LENZ Therapeutics, Inc. (LENZ) Stock

LENZ Therapeutics, Inc. (LENZ) is a Healthcare stock trading at $4.68 (as of 2026-08-21), with a market capitalization of $147.05M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

LENZ Therapeutics, Inc. is a biopharmaceutical company developing and commercializing vision-related therapies in the United States. Its product candidates, LNZ100 and LNZ101, are in Phase III clinical trials for the treatment of presbyopia, and the company is headquartered in Del Mar, California.

Understand LENZ Therapeutics, Inc.: how it makes money

LENZ Therapeutics develops and commercializes vision-improving biopharmaceutical therapies in the United States, including VIZZ, and its revenue in the latest period includes regulatory milestone license revenue recognition plus currently immaterial VIZZ net product revenue.

The profit model is currently driven more by regulatory milestone license revenue recognition than by VIZZ product sales, since VIZZ net product revenue is 0.0 in the latest period while major clinical progress is tied to Phase III candidates (LNZ100 and LNZ101).

Revenue by segment (latest quarter)
FDA Milestones$0.0B
China Milestones$0.0B
VIZZ Net Product$0.0B

Business quality (Weak): Commercial traction metrics are tracked (prescriptions, prescribing eye care professionals, and awareness), but near-term financial performance appears highly sensitive to regulatory milestones and the timing of meaningful VIZZ product revenue.

Bull case

  • Evidence of commercial activity in prescribing workflows: The latest-quarter KPIs include 25,000 Paid and Filled Prescriptions, with 20,000 filled prescriptions and 65,000 samples distributed (all figures provided).
  • Breadth of field engagement and awareness measurement: Reported KPIs include 6,500 unique eye care professionals, 98% aided awareness, and 79% unaided awareness (all figures provided).

Bear case

  • Revenue is small and appears milestone-dependent: In the latest period, VIZZ net product revenue is 0.0B, while regulatory milestone license revenue recognition is shown (0.01B for both FDA-based and China-based items).
  • Loss-making operating profile: Operating margin is -2321.7% in the latest period, indicating significant operating losses (as provided), with profitability potentially dependent on future regulatory and commercialization milestones.
Valuation — source: SEC EDGAR (first-party)
Price$4.68
Market Cap$147.05M
Price / Book0.67
Price / Sales6.75
FCF Yield-120.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$19.09M
Net Margin-430.3%
Revenue Growth (YoY)123.2%
EPS Growth (YoY)21.8%
FCF Growth (YoY)16.9%
Financial Health — source: SEC EDGAR
Altman Z-Score3.23 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRA CAPITAL MANAGEMENT, L.P. ($38.24M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOEvert Schimmelpennink
Employees6
CountryUS
IPO Date2024-03-22

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Acumen Pharmaceuticals, Inc. (ABOS)
  • Coherus Oncology, Inc. (CHRS)
  • Protalix BioTherapeutics, Inc. (PLX)
  • Armata Pharmaceuticals, Inc. (ARMP)
  • Caribou Biosciences, Inc. (CRBU)
  • Humacyte, Inc. (HUMA)
  • Invivyd, Inc. (IVVD)
  • Black Diamond Therapeutics, Inc. (BDTX)
LENZ earnings history · LENZ institutional & insider holders · LENZ KPIs & operating metrics · LENZ financials · LENZ investor presentations & press releases · LENZ SEC filings · LENZ peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.